Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024 - Infection et Inflammation
Article Dans Une Revue Vaccine Année : 2024

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024

Marine Maurel
  • Fonction : Auteur
Esther Kissling
  • Fonction : Auteur
  • PersonId : 1089378

Résumé

In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case–control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26–53 %) overall, 48 % (95 % CI: 31–61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3–49 %) at 6–14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.
Fichier principal
Vignette du fichier
1-s2.0-S0264410X24006443-main.pdf (611.89 Ko) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-04608441 , version 1 (11-06-2024)

Licence

Identifiants

Citer

Charlotte Laniece Delaunay, Aryse Melo, Marine Maurel, Clara Mazagatos, Luise Goerlitz, et al.. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024. Vaccine, 2024, 42 (19), pp.3931-3937. ⟨10.1016/j.vaccine.2024.05.067⟩. ⟨hal-04608441⟩
106 Consultations
71 Téléchargements

Altmetric

Partager

More